Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

NCT04384484 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.

NCT NCT04384484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04384484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Lead sponsor
ADC Therapeutics S.A.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 16, 2020
Completion date
June 30, 2028
Enrollment
440 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma